Incyte Corporation vs Levi Strauss & Co. — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while Levi Strauss & Co. trades at $22.95 (market cap $8.75B). The key difference: Incyte Corporation is far larger — about 2.8× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays a 2.81% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | LEVI | |
|---|---|---|
Market Cap | $24.54B | $8.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $25.53 |
52-Week Low | $81.61 | $17.92 |
Enterprise Value | $20.04B | $10.07B |
Dividend Yield | — | 2.81% |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →